By contrast, the new gene therapy only requires a single dose, and most patients in the study did not need to resume prophylactic factor IX treatments. "We hear from people born with hemophilia ...
The first dose, which is much smaller, prepares the immune system to respond more powerfully to the second, larger dose. This study, which was performed by bringing together computational modeling ...
The first dose, which is much smaller, prepares the immune system to respond more powerfully to the second, larger dose. This study, which was performed by bringing together computational modeling ...